Laddar...
Will the PCSK9 Inhibitors Be Employers’ “Line in the Sand”?
After the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C, employers have become very sensitive to new, and especially unforeseen, factors that significantly raise healthcare costs. With the recent launch of the proprotein convertase su...
Sparad:
| I publikationen: | Am Health Drug Benefits |
|---|---|
| Huvudupphovsman: | |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Engage Healthcare Communications, LLC
2016
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5004813/ https://ncbi.nlm.nih.gov/pubmed/27606041 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|